Malignant tumor metastasizing, comprised of several consecutive steps beginning with local cancer cell invasion, is a key factor which compromises the prognosis of cancer patients and is responsible for 90% of the lethal outcome. 2/3 of our diagnosed patients show with locally advanced process and/or metastatic disease (stage III/IV).
Researching key molecular and cellular mechanisms tied to development and metastasizing of laryngeal squamous cell carcinoma is of clinical importance to developing and using molecular target therapy.
Based on popular literature studies the emphasize was put on the following genes: TP53, CDKN2A – accentuating on exons 1,2,3, and PIK3CA – exons 9, 20, as primarily connected to the higher mutation potential of laryngeal squamous cell carcinoma.
Researching the genetic similarity between carcinoma and metastasis could potentially help understanding the genotype and mutation potential of Head and Neck squamous cell carcinomas. The practical potential use of this knowledge is the developing of predictive markers and better therapeutic algorithms for diagnosed patients.
----------------------------------------------------------------------
Туморното метастазиране, включващо няколко последователни стъпки, започвайки от инвазия на раковите клетки в околните тъкани, е ключовият фактор, който компрометира прогнозата на раково болните пациенти и отговаря за 90% от смъртността. 2/3 от диагностицираните пациенти са с локално авансирал процес и/ или метастатична болест (стадий III или IV).
Проучването на молекулярни и клетъчни механизми, водещи до формирането и метастазирането на плоскоклетъчния карцином от ларингеален произход, би било от клинична полза за разработването на молекулярна таргетна терапия.
На базата на обширен литературен обзор акцентът е поставен върху следните гени – TP53, CDKN2A – exons 1,2,3 and PIK3CA – exons 9, 20, като потенциални отговорници за повишаване метастатичния потенциал на плосколетъчния карцином от ларингеален произход.
Изследването на генетично сродство между карцином и метастаза би имало теоретичен принос към опознаването на генотипа и мутационния статус на плоскоклетъчните карциноми на глава и шия, чийто практически потенциал се изразява като прогностична стойност за преживяемостта на онкоболните и подобряване на терапевтичния алгоритъм при диагностицирани пациенти.
Guervós MA, Marcos CÁ, Hermsen M, Nuño AS, Suárez C, Llorente JL. Deletions of N33, STK11 and TP53 Are Involved in the Development of Lymph Node Metastasis in Larynx and Pharynx Carcinomas [Internet]. Analytical Cellular Pathology. 2007 [cited 2018 Nov 16]. Available from: https://www.hindawi.com/journals/acp/2007/635962/abs/
Zhou G, Liu Z, Myers JN. TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response. J Cell Biochem [Internet]. 2016 Dec [cited 2018 Nov 19];117(12):2682–92. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493146/
Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011 Aug 26;333(6046):1154–7.
Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 1993 Oct 1;53(19):4477–80.
Cai Y, Dodhia S, Su GH. Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma. Oncotarget [Internet]. 2017 Jan 18 [cited 2018 Nov 16];8(13):22203–17. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400658/
Qiu W, Tong G-X, Manolidis S, Close LG, Assaad AM, Su GH. Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer. Int J Cancer. 2008 Mar 1;122(5):1189–94.
Qiu W, Schönleben F, Li X, Ho DJ, Close LG, Manolidis S, et al. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2006 Mar 1;12(5):1441–6.
Kong D, Yamori T, Yamazaki K, Dan S. In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA. Invest New Drugs. 2014 Dec;32(6):1134–43.
Ihle NT, Williams R, Chow S, Chew W, Berggren MI, Paine-Murrieta G, et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther. 2004 Jul;3(7):763–72.
Liu N, Rowley BR, Bull CO, Schneider C, Haegebarth A, Schatz CA, et al. BAY 80–6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models. Mol Cancer Ther. 2013 Nov;12(11):2319–30.
Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D: RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 11:761–74, 2011. [A description of how RAS oncogenes activate multiple downstream signaling pathways to drive cellular transformation and oncogenesis.
Goh AM, Coffill CR, Lane DP: The role of mutant p53 in human cancer. J Pathol 223:116–26, 2011. [Discussion of emerging oncogenic roles of mutant p53 proteins]
фиг. 1. ROBBINS AND COTRAN PATHOLOGIC BASIS OF DISEASE, Ninth Edition ISBN: 978–1-4557–2613–4
фиг. 2. R. Zhao, B. Choi, M. Lee, A. Bode and Z. Dong, Implications of Genetic and Epigenetic Alterations of CDKN2A (p16 ) in Cancer, EBioMedicine (2016). Vol. 8
фиг 3. Qiyan, Wang & Bai, Jian & Abliz, Amir & Liu, Ying & Gong, Kenan & Li, Jingjing & Shi, Wenjie & Pan, Yaqi & Liu, Fangfang & Lai, Shujuan & Yang, Haijun & Lu, Changdong & Zhang, Lixin & Chen, Wanwan & Xu, Ruiping & Cai, Hong & Ke, Yang & Zeng, Changqing. (2015). An Old Story Retold: Loss of G1 Control Defines A Distinct Genomic Subtype of Esophageal Squamous Cell Carcinoma. Genomics, proteomics & bioinformatics. 13. 10.1016/j.gpb.2015.06.003.
